Last updated 01/05/2021

Primary care rebate schemes (PCRS) are contractual arrangements offered by pharmaceutical companies, or third party companies, which offer retrospective financial rebates to the CCG on GP prescribing expenditure for particular branded medicine(s).

The availability of a scheme does not influence the inclusion of specific medicines in care pathways or formularies.

Any decision to accept a PCRS is only made once a clinical decision to approve the use of a medication has been agreed locally.

We are unable to publish the full details of the PCRS because this information is commercially sensitive.

Although there are a number of PCRS available, NHS Salford CCG is currently signed up to the following:

Companies involved Drugs covered Generic names Start date End date
Takeda UK Limited Prostap Leuprorelin acetate Dec-15 Open-ended
Ferring Pharmaceuticals Firmagon degarelix Jan-17 Dec-21
Fontus Health Limited

Luventa XL,
Zaluron XL

Galantamine,
Quetiapine

 Mar-17 Open-ended
Kyowa Kirin International plc Adcal D3 Calcium carbonate & colecalciferol Apr-17 Open-ended
Merck Serono Limited Glucophage SR Metformin Apr-17 Feb-23

Sanofi Aventis

Apidra,

Insuman

Insulin glulisine,

Isophane insulin		 Apr-17 Jun-22
Ethypharm UK Ltd Xaggitin XL

Methlyphenidate

 Jun-20 May-22
Chiesi Ltd Clenil Modulite Belcometasone Jul-20 Jun-22
ConvaTec Ltd Dressings N/A Jul-20 Jun-22
Daiichi Sankyo UK Ltd Lixiana Edoxoban Jul-20 Dec-24

Syri Limited

Zacco

Clobazam

 May-21 Apr-23